Efficacy and Safety of NVX-CoV2705

Inclusion criteria

• . Adults 50 to \< 65 years of age at time of study vaccination (Day 0) who are not considered to be at high risk of severe COVID-19.
• . Participants unvaccinated to SARS-CoV-2 or participants previously vaccinated with a COVID-19 vaccine ≥ 90 days prior to study vaccination.
• . Participant or legally acceptable representative is willing and able to give informed consent prior to study enrollment and to comply with study procedures.
• . Female participants of childbearing potential (defined as any participant who has experienced menarche and who is NOT surgically sterile \[ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy\] or postmenopausal \[defined as amenorrhea ≥ 12 consecutive months\]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through 90 days after vaccination OR agree to consistently use a medically acceptable method of contraception listed below from ≥ 28 days prior to enrollment and through 90 days after vaccination.
• . Condoms (male or female) with spermicide (if acceptable in country)
• . Diaphragm with spermicide
• . Cervical cap with spermicide
• . Intrauterine device

Exclusion criteria